Tumor inflamatorio miofibroblástico peritoneal. Respuesta favorable asociada a infliximab: Caso clínico
Myofibroblastic tumor (MIT) is characterized by the infiltration of different organs, most commonly the lungs, with nodular lesions composed of myofibroblasts and inflammatory cells, which can be identified by specific patterns in the immunohistochemical studies. When it involves the peritoneum it i...
Guardado en:
Autores principales: | Grünholz,Daniela, Appiani,Franco, Abarca,Constanza, Manríquez,María, Pinilla,Jorge, Wainstein,Eduardo |
---|---|
Lenguaje: | Spanish / Castilian |
Publicado: |
Sociedad Médica de Santiago
2015
|
Materias: | |
Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015000700017 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald T, et al.
Publicado: (2021) -
Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction
por: Youlian Zhou, et al.
Publicado: (2018) -
Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model
por: David Ternant, et al.
Publicado: (2021) -
Remicade® (infliximab): 20 years of contributions to science and medicine
por: Melsheimer R, et al.
Publicado: (2019) -
Familial benign chronic pemphigus (Hailey-Hailey Disease): use of topical immunomodulators as a modern treatment option
por: Tchernev,Georgi, et al.
Publicado: (2011)